Sandoz Group AG | WebDisclosure

PRESS RELEASE

published on 11/04/2025 at 22:05, 5 months 21 days ago

Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
Sandoz strengthens biosimilars capabilities with acquisition of Just-Evotec Biologics EU SAS in Toulouse. Acquisition aims to capture projected biosimilar market opportunity. Transaction includes cash payment and technology license fees

Acquisition Biosimilars Sandoz Just-Evotec Biologics Continuous Manufacturing Technology
BRIEF

published on 10/30/2025 at 07:05, 5 months 26 days ago

Sandoz annonce une croissance de ses ventes et une révision à la hausse de ses prévisions de marge.

Croissance Des Ventes Biosimilaires Performance Régionale Orientation Financière Questions Commerciales
BRIEF

published on 10/30/2025 at 07:05, 5 months 26 days ago

Sandoz Reports Growth in Sales and Upgraded Margin Guidance

Financial Guidance Sales Growth Biosimilars Regional Performance Trade Issues
PRESS RELEASE

published on 10/30/2025 at 07:00, 5 months 26 days ago

Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded
Sandoz reports 5% growth in net sales for 9 months, with biosimilars contributing over 30%. Full-year margin guidance raised to 21-22% core EBITDA

EBITDA Net Sales Biosimilars Sandoz Margin Guidance
BRIEF

published on 09/09/2025 at 07:05, 7 months 16 days ago

Sandoz et Regeneron règlent un litige en matière de brevets

Approbation De La FDA Biosimilaire Sandoz Regeneron Aflibercept
BRIEF

published on 09/09/2025 at 07:05, 7 months 16 days ago

Sandoz and Regeneron Resolve Patent Dispute

FDA Approval Biosimilar Sandoz Regeneron Aflibercept
PRESS RELEASE

published on 09/09/2025 at 07:00, 7 months 16 days ago

Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar
Sandoz reaches agreement with Regeneron on patent litigation related to US aflibercept biosimilar, enabling launch of Enzeevu™ by end of 2026. Agreement strengthens Sandoz biosimilar portfolio and expands US market growth strategy

Biosimilar Patent Litigation Sandoz Regeneron Enzeevu
BRIEF

published on 08/28/2025 at 07:05, 7 months 28 days ago

Sandoz élargit l'accès au rivaroxaban en Allemagne

Allemagne Brevet Sandoz Rivaroxaban Antithrombotique
BRIEF

published on 08/28/2025 at 07:05, 7 months 28 days ago

Sandoz Expands Rivaroxaban Access in Germany

Patent Germany Sandoz Rivaroxaban Antithrombotic
PRESS RELEASE

published on 08/28/2025 at 07:00, 7 months 28 days ago

Sandoz launches rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options

Germany Sandoz Antithrombotic Treatment Rivaroxaban Generic Medicine

Published on 04/25/2026 at 03:10, 1 day 2 hours ago

BEACN Announces Financial Results for Year Ended December 31, 2025
Published on 04/24/2026 at 22:05, 1 day 7 hours ago

Critical Elements Mourns the Loss of Director Marc Simpson
Published on 04/24/2026 at 22:05, 1 day 7 hours ago

Critical Elements Pleure la perte de son administrateur Marc Simpson
Published on 04/24/2026 at 22:00, 1 day 7 hours ago

Kidoz Inc. to Present 2025 Results and Highlight Platform Expansion and Business Momentum
Published on 04/24/2026 at 15:00, 1 day 14 hours ago

Norsemont Reports Significant Copper, Lead & Zinc Values in Three Choquelimpie Drill Holes

View all ACCESSWIRE

Published on 04/25/2026 at 16:25, 13 hours 13 minutes ago

Leading a New Era of Family Mobility! CHERY TIGGO V, the 3-in-1 Family Vehicle, Debuts at AutoChina2026
Published on 04/24/2026 at 22:43, 1 day 6 hours ago

EQS-Adhoc: Marley Spoon Group SE: Closing of the financing transaction in connection with the financial restructuring of its German subsidiary Marley Spoon SE with increased financing amou
Published on 04/24/2026 at 22:05, 1 day 7 hours ago

Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study
Published on 04/24/2026 at 18:30, 1 day 11 hours ago

EUROPLASMA: Tirage de 400 obligations convertibles en actions nouvelles pour un montant nominal de 2M€
Published on 04/24/2026 at 18:12, 1 day 11 hours ago

EQS-Adhoc: clearvise AG reviews dividend proposal in line with its dividend strategy and postpones Annual General Meeting

View all EQS

Published on 04/25/2026 at 07:00, 22 hours 39 minutes ago

DLSI - Chiffre d'affaires 1er trimestre 2026
Published on 04/24/2026 at 18:48, 1 day 10 hours ago

Laboratoires Euromedis - Communiqué résultat 2025
Published on 04/24/2026 at 18:00, 1 day 11 hours ago

SMTPC - Communiqué sur la mise à disposition du Rapport annuel 2025
Published on 04/24/2026 at 17:45, 1 day 11 hours ago

Share buyback for cancellation
Published on 04/24/2026 at 17:45, 1 day 11 hours ago

Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026

View all LES ECHOS COMFI WIRE

News